Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals 123 6♦ patients from Britain and Ireland. However, the clinical experts acknowledged that such studies lack the methodological rigour typical of a clinical trial.’ In the end, ‘The committee concluded that it was unclear whether the DELTA population or the CUP cohort more closely reflected clinical practice and took both into account for decision making.’ Idelalisib was not recommended in the Final Appraisal Determination. ‘There are a wide range of cost-effectiveness estimates but, because the evidence is weak, idelalisib is not considered to represent a cost-effective use of NHS resources. Therefore, idelalisib cannot be recommended for routine use in the NHS.’
RkJQdWJsaXNoZXIy MTk4NDMw